Transcarent indicators settlement to accumulate Accolade for $621 million
US-based healthcare community Transcarent has agreed to accumulate Accolade, an organization specializing in healthcare advocacy, skilled medical recommendation and first care.
The deal has a complete fairness worth of practically $621 million, or $7.03 for every Accolade share.
It has been unanimously accepted by the boards of administrators of each firms and goals to offer a extra personalised and built-in healthcare platform.
The transaction will mix Transcarent's AI-powered WayFinding and complete healthcare experiences with Accolade's Personalised Healthcare Platform.
That is anticipated to create a unified platform that gives members with a single level of entry for his or her healthcare and healthcare wants, doubtlessly decreasing prices for healthcare customers, employers and payers.
WayFinding will present people with a single place for medical steering, advantages navigation and care supply, shifting from discrete options to a extra cohesive and personalised member expertise.
Achieve entry to essentially the most complete firm profiles available on the market, powered by GlobalData. Save hours of analysis. Achieve aggressive benefit.
Firm Profile – Free Pattern
Your obtain e-mail will arrive shortly
We now have confidence within the distinctive high quality of our firm profiles. Nevertheless, we would like you to take advantage of useful determination for your enterprise. That's why we give you a free pattern you can obtain by submitting the shape beneath.
By GlobalData
The brand new unified platform additionally goals to offer a “high quality first” expertise with quick access, lowered friction and paperwork for physicians, in addition to a “complete” level answer and native healthcare ecosystem.
Transcarent CEO Glen Tullman mentioned: “By integrating our not too long ago launched generative AI-powered WayFinding and complete healthcare experiences with Accolade's advocacy, skilled medical opinions and first care, we’ve got an answer that lastly makes it simple to entry high quality healthcare and concern. and decrease prices for the individuals who pay for well being care – employers and all of us.
“This mixture will speed up that course of, and I think about it an ideal match, including nice folks to our group and rising alternative and entry for our prospects and their staff and their households.”
The deal was funded with fairness financing from Common Catalyst and Glen Tullman's 62 Ventures.
The closing is predicted to happen within the second quarter of this yr, topic to approval by Accolade shareholders and regulators.
Following the deal, Accolade will grow to be a personal entity and be delisted from NASDAQ.
